↓ Skip to main content

Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions

Overview of attention for article published in Clinical Cancer Research, February 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet
patent
1 patent
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Published in
Clinical Cancer Research, February 2007
DOI 10.1158/1078-0432.ccr-06-1989
Pubmed ID
Authors

Brian I. Rini

Abstract

Renal cell carcinoma is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF). Recently, VEGF-targeted therapies have been identified as a promising therapeutic approach. Three agents targeting the VEGF pathway have shown clinical activity as monotherapy in metastatic renal cell carcinoma: the anti-VEGF monoclonal antibody, bevacizumab, and small-molecule VEGF receptor tyrosine kinase inhibitors, sorafenib and sunitinib. This article explores these agents in terms of their mechanisms of action, clinical efficacy, and toxicity profiles. This article also reviews future development strategies, including combination regimens and drug sequencing, trial design considerations, and patient selection opportunities.

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Hungary 1 1%
Poland 1 1%
Ireland 1 1%
Unknown 80 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 18%
Other 14 17%
Student > Ph. D. Student 12 14%
Student > Master 7 8%
Student > Bachelor 6 7%
Other 14 17%
Unknown 16 19%
Readers by discipline Count As %
Medicine and Dentistry 29 35%
Agricultural and Biological Sciences 15 18%
Biochemistry, Genetics and Molecular Biology 9 11%
Engineering 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 5 6%
Unknown 21 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 June 2022.
All research outputs
#1,997,572
of 21,673,824 outputs
Outputs from Clinical Cancer Research
#1,621
of 12,305 outputs
Outputs of similar age
#30,333
of 323,367 outputs
Outputs of similar age from Clinical Cancer Research
#30
of 181 outputs
Altmetric has tracked 21,673,824 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,305 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,367 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 181 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.